240 withdrawn. 240 Phase 3, 44 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 240 | Withdrawn 240 |
| Phase 2 | 44 | Withdrawn 44 |
Follow Neoplasms: new trials by email Literature Review of Neoplasms trials Research Report on Neoplasms
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| STENT X: a Randomized Trial to Assess Stent-free Radical Cystectomy ureteral stents, no ureteral stent - Bladder Cancer Requiring Cystectomy, Ureteral Stents | Phase 3 | Withdrawn | Brigham and Women's Hospital | 2026-09-01 | 2026-08-13 | |
| A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive) | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-06-30 | 2026-03-17 | |
| A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM) Linvoseltamab, Bortezomib, Lenalidomide - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Withdrawn | Regeneron Pharmaceuticals | 2026-06-05 | 2026-06-18 | |
| A Study Investigating Coagadex in the Treatment AFXD Associated With AL Amyloidosis Coagadex(R) - Acquired Factor X Deficiency | Phase 3 | Withdrawn | Kedrion S.p.A. | 2026-06-01 | 2026-06-29 | |
| Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin - NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-29 | 2026-06-22 | |
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) - NMIBC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-15 | 2026-05-19 | |
| A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT NDV-01 (sustained-release gemcitabine-docetaxel) - Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Bladder (Urothelial, Transitional Cell) Cancer | Phase 3 | Withdrawn | Relmada Therapeutics, Inc. | 2026-05-01 | 2026-03-17 | |
| A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-low Metastatic Breast Cancer Trastuzumab deruxtecan (T-DXd), Ribociclib with ET, Abemaciclib with ET - Metastatic Breast Cancer, ER-positive Breast Cancer | Phase 3 | Withdrawn | Danish Breast Cancer Cooperative Group | 2026-01-01 | 2026-02-12 | |
| Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC piflufolastat F 18 - Clear Cell Renal Cell Carcinoma | Phase 2 / Phase 3 | Withdrawn | Lantheus Medical Imaging | 2025-11-01 | 2025-12-10 | |
| The Impact of Intraoperative Methadone on Postoperative Opioid Use Methadon - Breast Cancer, Opioid Use | Phase 3 | Withdrawn | University of Utah | 2025-11-01 | 2025-11-26 | |
| Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer FP-014 - Prostate Cancer | Phase 3 | Withdrawn | Foresee Pharmaceuticals Co., Ltd. | 2025-07-01 | 2025-04-27 | |
| Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer Triptorelin Mesylate - Prostate Cancer | Phase 3 | Withdrawn | Foresee Pharmaceuticals Co., Ltd. | 2025-06-01 | 2025-04-27 | |
| Efficacy and Safety Study of EG1206A (EirGenix' Pertuzumab) Compared With EU-sourced Perjeta® (Pertuzumab) in Patients With HER2-positive Hormone Receptor Negative Early Breast Cancer. EG1206A, Perjeta - Early Breast Cancer | Phase 3 | Withdrawn | EirGenix, Inc. | 2025-05-01 | 2025-10-14 | |
| A Clinical Study Comparing Chemotherapy Combined With PD-1 Inhibitor Versus Concurrent Chemoradiotherapy in Cervical Cancer Patients With Positive Lymph Nodes After Surgery: A Multicenter Randomized Controlled Clinical Trial Chemo-immunotherapy, CCRT - Cervical Cancers | Phase 2 / Phase 3 | Withdrawn | Women's Hospital School Of Medicine Zhejiang University | 2025-03-01 | 2025-12-16 | |
| A Study of HB-202/HB-201 With Pembrolizumab in Patients With HPV16+ Recurrent/Metastatic Oropharyngeal Cancer HB-202/HB-201 alternating 2-vector therapy, Placebo, Pembrolizumab - Oropharyngeal Squamous Cell Carcinoma Recurrent | Phase 2 / Phase 3 | Withdrawn | Hookipa Biotech GmbH | 2024-12-01 | 2025-06-22 | |
| Immunoscore As Decision Guidance for Adjuvant Chemotherapy in Colon Cancer Capecitabine, Oxaliplatin, Fluorouracil - Colon Cancer Stage III | Phase 3 | Withdrawn | Johannes Laengle, MD, PhD | 2024-12-01 | 2024-09-20 | |
| Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma Brigimadlin, Ezabenlimab, Gemcitabine - Advanced Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma (UPS) | Phase 3 | Withdrawn | Boehringer Ingelheim | 2024-06-27 | 2024-07-17 | |
| Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein Telisotuzumab Vedotin, Osimertinib, Cisplatin - Non-Small Cell Lung Cancer | Phase 3 | Withdrawn | AbbVie | 2024-05-31 | 2024-06-26 | |
| A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) Alnuctamab, Pomalidomide, Daratumumab - Multiple Myeloma | Phase 3 | Withdrawn | Celgene | 2024-05-03 | 2024-05-31 | |
| Lactobacillus Lozenges as Preventative Care in Low-grade Dysplasia Probiotic oral lozenges, Standard of care for oral dysplasia - Low-grade Oral Dysplasia | Phase 3 | Withdrawn | Boston Medical Center | 2024-04-29 | 2024-05-01 |
Showing 20 of 240. Sign in to see all of them.
Breast Neoplasms (29) · Prostatic Neoplasms (17) · Carcinoma, Non-Small-Cell Lung (16) · Carcinoma, Hepatocellular (15) · Head and Neck Neoplasms (12) · Colorectal Neoplasms (10) · Ovarian Neoplasms (9) · Urinary Bladder Neoplasms (9) · Lung Neoplasms (8) · Squamous Cell Carcinoma of Head and Neck (8) · Leukemia (7) · Leukemia, Myeloid, Acute (7) · Lymphoma, Follicular (7) · Neoplasm Metastasis (7)
Neoplasms by Site (163) · Neoplasms by Histologic Type (114) · Neoplasms, Glandular and Epithelial (62) · Urogenital Diseases (52) · Digestive System Diseases (46) · Carcinoma (45) · Digestive System Neoplasms (45) · Urogenital Neoplasms (45) · Hemic and Lymphatic Diseases (41) · Pathological Conditions, Signs and Symptoms (39) · Female Urogenital Diseases (38) · Female Urogenital Diseases and Pregnancy Complications (38) · Skin and Connective Tissue Diseases (38) · Genital Diseases (35)
Cisplatin (24) · Carboplatin (17) · Gemcitabine (14) · Paclitaxel (14) · Radiotherapy (14) · Fluorouracil (12) · Oxaliplatin (8) · Rituximab (8) · Bevacizumab (6) · Capecitabine (6) · Dexamethasone (6) · Docetaxel (6) · Drug Therapy (6) · Leucovorin (6) · Cyclophosphamide (5)
European Organisation for Research and Treatment of Cancer - EORTC (7) · Novartis Pharmaceuticals (5) · AstraZeneca (4) · Bristol-Myers Squibb (4) · Guangxi Medical University (4) · Incyte Corporation (4) · Merck Sharp & Dohme LLC (4) · Alliance for Clinical Trials in Oncology (3) · Emory University (3) · Hadassah Medical Organization (3) · Hoffmann-La Roche (3) · M.D. Anderson Cancer Center (3) · Samsung Medical Center (3) · AbbVie (2) · Asan Medical Center (2)
United States (71) · China (21) · Canada (19) · South Korea (10) · Germany (9) · United Kingdom (9) · Belgium (8) · Brazil (8) · Italy (7) · France (6) · Australia (5) · Israel (5) · Spain (5) · Switzerland (5) · Austria (4)
Lequn Li, PhD (3) · Ming Shi, MD (3) · Igal Ruvinsky, PhD (2) · John Lahey (2) · Susan Whitaker, BSN, MS, MBA (2) · Ajay K Nooka (1)
PMID 17513820, PMID 19833819, PMID 20035187, PMID 20347506, PMID 20593535, PMID 21058409, PMID 21115882, PMID 23980077, PMID 25734980, PMID 26291918, PMID 26517756, PMID 26597311, PMID 26634942, PMID 26731686, PMID 26972555, PMID 28640161, PMID 31299087, PMID 32632956, PMID 37468392, PMID 38265030, PMID 38564122, PMID 38979716, PMID 40135712
2017 (7), 2018 (4), 2023 (2), P30CA016672 (2), 2014 (1), 2015 (1), 2016 (1), 2025 (1), P30CA014089 (1), P30CA016059 (1), P30CA022453 (1), P30CA042014 (1), P30CA072720 (1), P30CA138292 (1), R01CA080852 (1)